Does CTSO pay a dividend and is it safe?

Cytosorbents Corporation (CTSO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / CTSO / dividends

PAVM (28) GUTS (34) CNSY (25) SINT (33) ⌘ Pro Terminal →

Cytosorbents Corporation (CTSO) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.12 -9.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.04

Cytosorbents Corporation (CTSO) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $14.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTSO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.12 (-9.25% 1D, market cap $14.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTSO ranks #964 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CTSO compare to PAVM and GUTS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, PAVM (PAVmed Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M) and GUTS (Fractyl Health Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTSO?

▼

Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.04 (-1.85%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTSO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (22/100 Composite)

🔍 WHY CTSO SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.46+53.8% Next Q

Q2 (-2Q)

Grade E$5.32-8.8% Next Q

Q3 (-1Q)

Grade E$4.85-15.1% Next Q

Current

Grade E$4.12-11.4% Hist 90D α

Trajectory: E (15) → E (22)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTSO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTSO currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.18) and Max Pain ($4.33) forces dealer call-delta covering toward $17.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTSO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTSO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 22%NO 78%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTSO)

✓Walkthrough of CTSO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTSO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -66.77%▼ DESCENDING CHANNEL

2026-11-03O $4.40H $4.54L $4.12C $4.12VOL 24.1K

RES: $6.39SUP: $1.84SMA50: $5.18SMA200: $9.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTSO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTSO Butterfly Map → + Track CTSO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +4.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CTSO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTSO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTSO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTSO)

Health Care Rank #964 of 1015 ⚔️ PAVM vs CTSO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTSO vs. PAVM, GUTS, CNSY, SINT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cytosorbents Corporation (CTSO) ranks #964 by composite RQD confidence (22/100, grade E) and #858 by equity capitalization ($14.3M). Within this direct 5-issuer industry benchmark cohort, CTSO leads on earnings valuation at N/A trailing P/E, while CTSO leads on capital efficiency and profitability with -35.0% ROIC and 71.5% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with CTSO at 22/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTSO ACTIVE Cytosorbents Corporation	E	22/100	—	71.5%	-35.0%	-9.25%	$14.3M	Benchmark Subject
PAVM PAVmed Inc.	E	28/100	—	-30.0%	-35.0%	-2.05%	$15.6M	/pavm-vs-ctso →
GUTS Fractyl Health Inc.	E	34/100	—	—	-35.0%	-3.47%	$13.0M	/guts-vs-ctso →
CNSY Cerenome Inc.	E	25/100	—	—	-35.0%	+0.59%	$12.9M	/cnsy-vs-ctso →
SINT SiNtx Technologies Inc.	E	33/100	—	45.3%	-35.0%	+0.59%	$12.8M	/sint-vs-ctso →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001175151 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytosorbents Corporation (CTSO) reported GAAP revenue of $37.1M (+4.1% vs. FY2024 revenue of $35.6M , and -58.6% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$12.4M, and free cash flow of -$12.5M (+14.8% YoY). On the balance sheet, CTSO closed FY2025 with $44.2M in total assets against $16.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$37.1M	-$8.2M	-$12.4M	-$12.5M	$44.2M	$16.7M
FY2024 (FY)	2024-12-31	$35.6M	-$20.7M	-$14.4M	-$14.7M	$47.4M	$14.0M
FY2023 (FY)	2023-12-31	$89.5M	-$29.2M	-$21.7M	-$21.7M	—	—

3. CTSO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CTSO compare to PAVM and GUTS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CTSO?

Where is CTSO trading relative to its 50-day, 200-day, and 52-week technical levels?

CTSO last traded at $4.12 (-9.25% on volume of 24,323 shares), positioning the stock -20.46% below its 50-day simple moving average ($5.18) and -56.17% below its 200-day simple moving average ($9.40). Across its 52-week range of $2.84 to $17.00, CTSO sits at the 9.0% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.60 to $4.64).

Direct Sub-Reports: CTSO RQD Cockpit CTSO 12M Forecast CTSO Earnings & Move CTSO Dividends & DRIP CTSO Insiders & 13F CTSO Whale Options CTSO Profit Sankey CTSO News & Why

ROARABLE RATING BRIEF • RQD 22/100 (E) ✓ SEC XBRL & RQD VERIFIED

CTSO — Cytosorbents Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cytosorbents Corporation (CTSO) earns a live Roarable RQD composite score of 22/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.12 (-9.25% 1D, market capitalization $14.3M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 71.5%, operating margin of -39.8%, and free cash flow yield of —.
Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of 2.82x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cytosorbents Corporation (CTSO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is a Health Care issuer in this industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cytosorbents Corporation (CTSO) reported $37.1M in annual revenue (up from $35.6M in FY2024, +4.1% YoY) and -$8.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($89.5M revenue, -$29.2M net income) through FY2025, CTSO scaled operating cash flow to -$12.4M and free cash flow to -$12.5M, backed by $44.2M in total assets against $16.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 22/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.84 – $17.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -39.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), CTSO carries a macro regime beta of 1.00 and gross margin of 71.5%.

Key Question #1: Can CTSO sustain or expand its -39.8% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $37.1M and free cash flow of -$12.5M, how will capital allocation balance growth reinvestment against $16.7M in total debt?
Key Question #3: How sensitive is CTSO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CTSO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cytosorbents Corporation (CTSO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CTSO Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 21h ago

Cytosorbents Corporation Estimates – NASDAQ:CTSO

TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Cytosorbents Corporation (CTSO) Seasonal returns chart

Yahoo Finance UK report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

WBB Securities initiates CytoSorbents stock with Speculative Buy

Investing.com report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A live Q&A follows CytoSorbents' third-quarter results on Nov. 12.

Stock Titan report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 1d ago

CytoSorbents (NASDAQ:CTSO) Schedules Q3 2026 Results Announcement and Recent Business Update

Kalkine report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CTSO Q3'26 Earnings: revenue estimate is 9.90M USD

TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CTSO Q3'26 Earnings: EPS estimate is (0.90) USD

TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 5d ago

CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTSO Bull vs. Bear Conversation Board — What's Your Call at $4.12?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTSO 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $5.40 (+18.9%)

📌 Pinned Debate

Revenue grew from $35.6M in FY 2024 to $37.1M in FY 2025 while net loss narrowed from -$20.7M to -$8.2M.

Don't sleep on CTSO's setup in Health Care. Revenue grew from $35.6M in FY 2024 to $37.1M in FY 2025 while net loss narrowed from -$20.7M to -$8.2M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (22/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

Both sides have a point here — CTSO's 6/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.68 (-18.9%)

Spot @ $4.54

A negative 35% ROIC, 0% FCF yield, and a Debt/Equity of 2.82 against $13.9M market cap leave little equity cushion.

Here is the bear case nobody on the bull side wants to address on CTSO: A negative 35% ROIC, 0% FCF yield, and a Debt/Equity of 2.82 against $13.9M market cap leave little equity cushion.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.